Colin T Murphy1, Karthik Devarajan2, Lora S Wang1, Ranee Mehra3, John A Ridge4, Christopher Fundakowski4, Thomas J Galloway5. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States. 2. Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, United States. 3. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States. 4. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States. 5. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address: thomas.galloway@fccc.edu.
Abstract
PURPOSE: To assess the relationship between tumor-specific growth rate (TSGR) and oropharyngeal cancer (OPC) outcomes in the HPV era. METHODS/MATERIALS: Primary tumor volume differences between a diagnostic and secondary scan separated ⩾7days without interval treatment were used to estimate TSGR, defined as percent volume growth/day derived from primary tumor volume doubling time for 85 OPC patients with known p16 status and smoking pack-years managed with (chemo)radiation. Variables were analyzed using Kruskal-Wallis or Fisher's exact test as appropriate. Log-rank tests and Cox proportional models analyzed endpoints. Using concordance probability estimates (CPE), TSGR was incorporated into RTOG 0129 risk grouping (0129RG) to assess whether TSGR could improve prognostic accuracy. RESULTS: Median time between scans was 35days (range 8-314). Median follow up was 26months (range 1-76). The 0129RG classification was: 56% low, 25% intermediate, and 19% high risk. Median TSGR was 0.74%/day (range 0.01-4.25) and increased with 0129RG low (0.41%), intermediate (0.57%) and high (1.23%) risk, respectively (p=0.015). TSGR independently predicted for TF (TSGR: HR (95%CI)=2.79, 1.67-4.65, p<0.001) in the Cox model. On CPE, prognostic accuracy for TF, disease-free survival and overall survival was improved when 0129RG was combined with TSGR. Dichotomizing 0129RG by median TSGR yielded no observed recurrences in low risk patients with TSGR<0.74% and demonstrated significant difference for intermediate risk (8% vs. 50% for TSGR<0.74% vs. ⩾0.74%, respectively, p<0.001). CONCLUSION: Tumor-specific growth rate correlates with increasing 0129RG and predicts treatment failure, potentially improving the prognostic strength and risk stratification of established 0129 risk groups.
PURPOSE: To assess the relationship between tumor-specific growth rate (TSGR) and oropharyngeal cancer (OPC) outcomes in the HPV era. METHODS/MATERIALS: Primary tumor volume differences between a diagnostic and secondary scan separated ⩾7days without interval treatment were used to estimate TSGR, defined as percent volume growth/day derived from primary tumor volume doubling time for 85 OPCpatients with known p16 status and smoking pack-years managed with (chemo)radiation. Variables were analyzed using Kruskal-Wallis or Fisher's exact test as appropriate. Log-rank tests and Cox proportional models analyzed endpoints. Using concordance probability estimates (CPE), TSGR was incorporated into RTOG 0129 risk grouping (0129RG) to assess whether TSGR could improve prognostic accuracy. RESULTS: Median time between scans was 35days (range 8-314). Median follow up was 26months (range 1-76). The 0129RG classification was: 56% low, 25% intermediate, and 19% high risk. Median TSGR was 0.74%/day (range 0.01-4.25) and increased with 0129RG low (0.41%), intermediate (0.57%) and high (1.23%) risk, respectively (p=0.015). TSGR independently predicted for TF (TSGR: HR (95%CI)=2.79, 1.67-4.65, p<0.001) in the Cox model. On CPE, prognostic accuracy for TF, disease-free survival and overall survival was improved when 0129RG was combined with TSGR. Dichotomizing 0129RG by median TSGR yielded no observed recurrences in low risk patients with TSGR<0.74% and demonstrated significant difference for intermediate risk (8% vs. 50% for TSGR<0.74% vs. ⩾0.74%, respectively, p<0.001). CONCLUSION:Tumor-specific growth rate correlates with increasing 0129RG and predicts treatment failure, potentially improving the prognostic strength and risk stratification of established 0129 risk groups.
Authors: Daniel Dejaco; Teresa Steinbichler; Volker Hans Schartinger; Natalie Fischer; Maria Anegg; Joszef Dudas; Andrea Posch; Gerlig Widmann; Herbert Riechelmann Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692